# A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel

Source: https://onco.cc/trials/nct05805501/  
OnCo record `nct05805501` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tiragolumab, Pembrolizumab, Axitinib in renal cell carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma is a phase 2 interventional study registered as NCT05805501 by Hoffmann-La Roche, with 199 participants enrolled, started 2023-04-21 and due to reach its primary completion in 2026-10-08. Interventions recorded: Tobemstomig, Tiragolumab, Pembrolizumab, Axitinib. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05805501
- Phase: 2
- Setting: A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
- Sponsor: Hoffmann-La Roche
- Enrolled: 199

## Sources

- ClinicalTrials.gov NCT05805501: https://clinicaltrials.gov/study/NCT05805501

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Axitinib](https://onco.cc/drugs/axitinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Tiragolumab](https://onco.cc/drugs/tiragolumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct05805501.json